Usage Information
Citation Information: J Clin Invest. 2006;116(4):892-904. https://doi.org/10.1172/JCI25901.
Abstract
Vitamin D receptor (VDR) ligands are therapeutic agents for the treatment of psoriasis, osteoporosis, and secondary hyperparathyroidism. VDR ligands also show immense potential as therapeutic agents for autoimmune diseases and cancers of skin, prostate, colon, and breast as well as leukemia. However, the major side effect of VDR ligands that limits their expanded use and clinical development is hypercalcemia that develops as a result of the action of these compounds mainly on intestine. In order to discover VDR ligands with less hypercalcemia liability, we sought to identify tissue-selective VDR modulators (VDRMs) that act as agonists in some cell types and lack activity in others. Here, we describe LY2108491 and LY2109866 as nonsecosteroidal VDRMs that function as potent agonists in keratinocytes, osteoblasts, and peripheral blood mononuclear cells but show poor activity in intestinal cells. Finally, these nonsecosteroidal VDRMs were less calcemic in vivo, and LY2108491 exhibited more than 270-fold improved therapeutic index over the naturally occurring VDR ligand 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] in an in vivo preclinical surrogate model of psoriasis.
Authors
Yanfei Ma, Berket Khalifa, Ying K. Yee, Jianfen Lu, Ai Memezawa, Rajesh S. Savkur, Yoko Yamamoto, Subba R. Chintalacharuvu, Kazuyoshi Yamaoka, Keith R. Stayrook, Kelli S. Bramlett, Qing Q. Zeng, Srinivasan Chandrasekhar, Xiao-Peng Yu, Jared H. Linebarger, Stephen J. Iturria, Thomas P. Burris, Shigeaki Kato, illiam W. Chin,, Sunil Nagpal
Usage data is cumulative from April 2024 through April 2025.
| Usage | JCI | PMC |
|---|---|---|
| Text version | 535 | 27 |
| 54 | 25 | |
| Figure | 0 | 5 |
| Citation downloads | 65 | 0 |
| Totals | 654 | 57 |
| Total Views | 711 | |
Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.
Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)